
TB-500
Also called Ac-LKKTETQ, thymosin beta-4 fragment, tb500, TB4 fragment
A fragment of a repair protein, with no human trial of its own
TB-500 is a short synthetic fragment of thymosin beta-4, a protein the body makes that helps cells move to damaged tissue. It is most often discussed for tendon, muscle and joint injuries. The human trials that exist used the full protein for dry eye and leg ulcers, not the fragment for sports injuries. It is not an approved medicine.
TB-500 is a short seven-amino-acid fragment copied from the middle of a much larger protein your body makes called thymosin beta-4. That protein is 43 amino acids long and helps cells travel to the site of an injury; TB-500 is the small piece of it thought to do that job. The human trials used the full protein, not the fragment, and the name TB-500 is applied to both, which makes much of what is written about it ambiguous.
- Route studied
- Eye drop, topical, intravenous (protein trials)
- Status
- Not FDA-approved
Human trials published, with more underway
1,045 papers · 8 clinical trials
What TB-500 has been studied for
The reasons people look it up, roughly in order of how often, and what research exists for each. Interest in a use is not evidence that it works; the evidence is stated under each one.
Mechanism of Action
How TB-500 works
For a cell to reach an injury, it has to crawl. Cells move by building an internal scaffold at the front, pulling themselves forward, then dismantling it behind and rebuilding it further on. The scaffold is made of a protein called actin, and the crawl only works if there is a ready supply of loose actin to build with.
Thymosin beta-4 is the protein that manages that supply. It holds loose actin in reserve and releases it where building is needed, so cells can migrate toward damage rather than sitting still.
TB-500 is a short piece cut out of that protein, the part thought to do the actin holding.
The distinction that changes how you read everything
A fragment is not the protein. TB-500 is seven amino acids; thymosin beta-4 is 43. They are related the way a sentence is related to a paragraph it was taken from.
This matters because the human studies people cite used the full protein, not the fragment. And they tested severe dry eye and venous leg ulcers, using eye drops and topical treatment.
So the safety data is genuinely reassuring about a 43-amino-acid protein given to healthy volunteers, and it says very little about a seven-amino-acid fragment used for a torn tendon. That is the use people most often ask about, and it is the one use nobody has trialled in people.
Why it is mentioned with BPC-157
The usual argument is that one acts locally and the other travels. It is a tidy story. Only one preclinical study has tested the two together, and no study in people has.
TB-500 side effects: what studies reported
There is no human trial of the fragment to build a formal table from. What follows are reports collected outside trials; the safety studies of the full protein reported it as well tolerated.
Reported outside trials
- Injection-site soreness or redness
- A head rush
- Tiredness or a heavy-limbed feeling
- Mild nausea
Worth keeping an eye on
- It promotes new blood vessel growth, which is the mechanism, so a cancer history is a conversation for an oncologist
- Reactions that worsen over a day rather than settle, which points to contamination or infection rather than the compound
Source: Reports outside trials, plus the safety studies of full thymosin beta-4. This is a summary of published findings, not a complete safety profile and not medical advice. Questions about TB-500 belong with a licensed clinician who knows your history.
Your Genetics & TB-500
The genes involved in how TB-500 works
TB-500 works through the receptors these genes build, and the genes vary from person to person. Researchers have linked some of that variation to differences in how people respond. A DNA report tells you which versions you carry.
MMP3 · ••
The 5A/6A promoter variant has been associated with differences in MMP3 expression, the enzyme that breaks down old tissue matrix, and studied for its link to tendon injury risk. No study has tested whether it changes response to TB-500.
Fibronectin is part of the scaffolding cells migrate along during wound healing. Variants in FN1 are studied for their association with tissue traits. Any link to TB-500 is a hypothesis; it has not been tested.
VEGFA · ••
Associated with differences in VEGF-A production, the main signal for new blood vessel growth, which thymosin beta-4 also promotes in preclinical work. Pathway context only: no study has tested whether this variant changes response to TB-500.
The dots after each gene are where your own result goes. Your report fills them in with the two letters you carry at that position.
Which of these variants do you carry?
Your report reads the DNA file you already have against this research.
Often discussed alongside
Compounds that come up next to TB-500 in research and discussion. Each has its own page. None of this is a suggestion to combine them.

BPC-157
the Wolverine pairingModerate EvidenceBody Protection Compound 157
BPC-157 comes up whenever people talk about injuries that will not heal: tendons, ligaments, a gut irritated by painkillers. It is a short chain of amino acids copied from part of a protein the stomach already makes, and the preclinical research on it is unusually consistent for this category: across many separate preclinical studies, injured tissue healed faster than it did without it. The gap is that this has largely not been repeated in people, and it is not an approved medicine, so no regulator checks the quality of what is sold under its name.
3
Gene variants
19+
Studies

GHK-Cu
tissue repair researchModerate EvidenceGlycyl-L-Histidyl-L-Lysine Copper Complex
A naturally occurring copper-binding tripeptide, studied mainly for wound healing and skin. It carries copper into tissue, where copper is the cofactor the enzyme that cross-links collagen cannot work without. Most of the evidence is topical or preclinical; the widely quoted gene-expression claims rest on far less than they appear to.
4
Gene variants
100+
Studies
Named combinations
A combination people search for by name, and what research exists on it.
Access
Access and legal status
TB-500 is not an FDA-approved drug. Products sold online as “research chemicals” are labelled not for human use, and FDA treats them as unapproved drugs when they are marketed for people. We don't link to any seller, and nothing on this page is a recommendation to obtain or use it.
Your DNA and TB-500: see which of the variants studied alongside it you carry, and what that research does and does not show. Read my DNA, $99 →
Educational information only, not medical advice. Most peptides are not FDA-approved. Do not start, stop or change any medication or peptide because of this page; talk to a licensed clinician.
Worth knowing about TB-500
Interactions and situations where there is a specific reason to be careful. Where the honest answer is that nobody has studied something, it says so and says what that leaves open.
- The fragment is not the molecule that was trialled
- Every human result here used full thymosin beta-4. TB-500 is a short piece of it, chosen because it is cheaper to make and contains the part thought to bind actin. Whether the fragment does everything the protein does has not been established in people.
- No human trial exists for the use it is known for
- Tendon, ligament and muscle repair is the entire case made for it, and it rests on preclinical studies. That is not the same as evidence of no effect, but it is a long way from the dry-eye and ulcer trials being cited as if they transfer.
- Banned in sport, and a caution about actively growing tumours
- It is prohibited under WADA rules at all times. Because thymosin beta-4 promotes new blood vessel growth and cell migration, which is how it helps tissue heal, it is a mechanism worth discussing with an oncologist if cancer is in the picture.
The evidence behind TB-500
Two distinctions decide how to read everything below. First, TB-500 is a seven-amino-acid fragment; the trials used full thymosin beta-4, a 43-amino-acid protein. They are related but not the same thing. Second, the human trials tested eye drops for dry eye and topical treatment for leg ulcers. Nobody has run a human trial of either molecule for tendon or muscle injury, so the safety data below is genuinely reassuring about the protein and tells you little about the fragment.
The literature, counted
Counted in PubMed on 3 August 2026 for thymosin beta 4 OR TB-500. Every figure links to the search that produced it, so you can re-run it. “Tagged human” is not the same as a human trial: that tag also covers work on human cells and reviews discussing people, which is why the trial count is given separately.
Studied in people
3 of 4The only kind that directly answers whether it works in humans.Cornea · 2015
HumanThymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial
Sosne G, Dunn SP, Kim C
The clearest positive human result for thymosin beta-4: a randomised trial in severe dry eye reporting improvement in both signs and symptoms. It was an eye drop, using the full protein.
Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial: source for TB-500 (opens in a new tab)Phase 2
Read the paperAnnals of the New York Academy of Sciences · 2010
HumanA randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers
Ruff D, Crockford D, Girardi G, Zhang Y
The human safety study, giving thymosin beta-4 intravenously to healthy volunteers in single and repeated doses against placebo. This is the source of the claim that it is well tolerated, and it is worth knowing it tested the protein rather than TB-500.
A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers: source for TB-500 (opens in a new tab)Read the paperAnnals of the New York Academy of Sciences · 2007
HumanThymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on wound healing
Guarnera G, De Rosa A, Camerini R
A European randomised study in venous leg ulcers, the other place the protein has been properly tested in people. Wound healing, not sports injury.
Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on wound healing: source for TB-500 (opens in a new tab)Read the paper
Every source behind this page63 more
- A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of thymosin β4Wang X, Liu L, Qi L, et al. · Journal of Cellular and Molecular Medicine · 2021 · Phase 1Human
- Thymosin beta4: actin-sequestering protein moonlights to repair injured tissuesGoldstein AL, Hannappel E, Kleinman HK · Trends in Molecular Medicine · 2005Review
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine PhysiciansMayfield CK, Bolia IK, Feingold CL, et al. · American Journal of Sports Medicine · 2026Review
Everything we cite for TB-500, including preclinical work and early research. Each link goes to the source itself, so you can judge it rather than take our word for it.
Last updated · literature counts verified against PubMed on
Frequently Asked Questions
What has TB-500 been studied for?
The fragment itself has only preclinical research, mostly on tendon, muscle and wound repair. The full protein it comes from, thymosin beta-4, has human trials as an eye drop for severe dry eye and as a topical treatment for venous leg ulcers. No human trial has tested either molecule for sports injuries, and TB-500 is not an approved medicine.
How is TB-500 different from BPC-157?
They come from different proteins and are described as acting differently: BPC-157 mainly on blood flow and new vessel growth near an injury, TB-500 on how cells move. Both are studied mostly in preclinical models. They are often discussed together as the 'Wolverine stack', which has one preclinical study and no human trial.
Do genes change how TB-500 works?
No study has tested whether any genotype changes response to TB-500. The genes above (MMP3, FN1, VEGFA) sit on the tissue-remodelling and blood-vessel pathways it is studied on. A DNA report can show which versions you carry and what that research does and does not show.
Watch
What clinicians and researchers say about TB-500
20 minExposing The Truth About PeptidesDoctor Mike · ClinicianBPC-157TB-500KPV
1 hr 30 minPeptide Expert: What Do Peptides Actually Do? (EXPLAINED) - Dr Alex TatemThe Diary of a CEO · PodcastBPC-157TB-500MOTS-c
2 hr 48 minPeptides: The Science, Uses & Safety | Dr. Abud BakriAndrew Huberman · ResearcherBPC-157TB-500Thymosin Alpha-1Learn more about TB-500
11 guides mention TB-500→how it works
In depthTB-500 and BPC-157 half-life: what the pharmacokinetic studies actually measured
8 min read
comparisons
In depthBPC-157 vs TB-500 for muscle injury: what the research actually tested
9 min read
peptide guides
5 peptides studied for tissue repair, and what the research actually found
9 min read
peptide guides
Peptides studied for muscle recovery and injury repair: 7 compounds sorted by human evidence
11 min read
safety
Are peptides legal in the US? 8 facts about FDA approval and compounding in 2026
10 min read
safety
Anti-drug antibodies and peptides: what the GLP-1 drug trials found
8 min read
Your DNA and TB-500
What the research says about your variants.
The report
Which TB-500 variants do you carry?
Your report reads the DNA file you already have against the published research on 31 peptides, marker by marker, and says what that research does and does not show.
Read my DNA, $99